- OpenAI and Anthropic have signed a letter urging Congress to adopt new laws aimed at preventing the misuse of AI technology in the development of biological weapons.
- The signatories of the letter include prominent CEOs from Google DeepMind, Microsoft AI, and various gene synthesis companies, advocating for laws that require the screening of customers and orders for synthetic DNA and RNA.
- The letter cautions that the rapid development of AI presents a real possibility of eroding historical knowledge barriers that currently prevent bad actors from obtaining biological weapons.
- David Relman, a microbiologist and biosecurity expert, highlighted that AI tools allow users to quickly identify how to order sequences that evade screening.
- Experts emphasize that companies should ensure the responsible use of DNA synthesis technology to prevent misuse in dangerous applications.
- Federal regulations introduced during the Biden administration mandate that federally funded scientists and companies must order screened synthetic gene sequences.
OpenAI and Anthropic, alongside other AI leaders, have signed a letter addressing Congress, pushing for stringent regulations on AI technologies to prevent misuse in biological weapons development. This initiative is fueled by concerns over the rapid advancements in AI that may lower barriers for malevolent actors.1
The letter, signed by notable figures like Demis Hassabis from Google DeepMind, Sam Altman from OpenAI, and Dario Amodei from Anthropic, emphasizes the importance of legislation demanding screening for those purchasing synthetic DNA and RNA. The urgency is underscored by the statement that “there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode.”23
Experts like David Relman, a microbiologist and biosecurity authority, warned that “AI tools enable a user to very quickly identify where to turn to order sequences that will not be subject to screening” which poses serious risks.4
Additionally, signing members emphasized the responsibility of companies involved in DNA synthesis to ensure ethical use. James Diggans, a vice president at Twist Bioscience, reiterated this by stating, “If you have technology that is capable of synthesizing DNA, then you should ensure that it's used responsibly.” The call to action highlights the imperative for additional controls, especially in light of potential screening failures in current federal guidelines.
As AI's role in bioengineering matures, the signatories advocate for proactive measures to safeguard against possible threats, highlighting the crucial need for cooperation between tech companies and regulatory frameworks.
“The CEOs of major AI companies are advocating for new regulations to control the use of synthetic DNA and RNA. They express concerns that the rapid advancement of AI could lead to an increased risk of biological weapon development by malicious actors.”
